Prostate Cancer
Advertisement
Preston Sprenkle, MD – Championing Prostate Cancer Diagnostics, Focal Therapy, and Patient Education
Dr. Sprenkle shares his inspiration to practice urologic oncology and his role in popularizing the Artemis Device.
Amar Kishan, MD gives an overview of the MIRAGE trial that compared MRI-guided and CT-guided SBRT for prostate cancer.
Can using a hyaluronic acid spacer mitigate rectal toxicity and reduce the gastrointestinal toxicity associated with RT?
A recent study compared the activity of taxanes with second-line androgen-receptor therapy in patients with mCRPC.
A study arm from the phase 3 EMBARK trial evaluating enzalutamide for nmCSPC with high-risk BCR has had positive outcomes.
Researchers used determined if an increase in ACM risk existed when sRT was delivered above a prespecified PSA level.
The new indication will improve access to imaging for approximately 32,000 candidates for radioligand therapy in the US.
A recent study analyzed a 15-year follow-up in men with prostate cancer to gauge the effectiveness of different treatments.
Researchers conducted a study to determine PSA response and MFS in patients with nmCRPC treated with APA.
Mutahar Ahmed, MD, discusses the history and current applications of single-port robotic surgery in prostate cancer.
Rachelle Rodriguez, MS, APRN, AOCNP, highlights her role in helping Moffitt grow its APP presence within the GU onc program.
This review highlights the research on the costs related to the treatment of localized PC and the associated outcomes.
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
Active Surveillance May Be Appropriate for Some Men With Favorable Intermediate-Risk Prostate Cancer
It is increasingly common for patients with favorable intermediate-risk PC to be managed with active surveillance.
Implementing sterilization techniques may reduce infectious complications associated with transrectal prostate biopsy.
Is it possible to avoid or delay systemic therapy for patients with oligometastatic prostate cancer? A new study suggests so.
Siddharth Ramanathan and Savitha Balaraman, MD, highlight an onsite genetic testing protocol for newly diagnosed with PC.
Drs. Howard Korman and Savitha Balaraman describe the importance of genetic testing for patients newly diagnosed with PC.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Scott Tagawa, MD, MS, FACP, shares what needs to happen for radionuclide therapy to make its way into the community setting.
Advertisement
670 Madison Ave.
Manalapan, NJ 07726